MSLs deployed in launch of Navidea diagnostic agent

Share this article:
MSLs deployed in launch of Navidea diagnostic agent
MSLs deployed in launch of Navidea diagnostic agent

Navidea Biopharmaceuticals is launching Lymphoseek, its diagnostic agent used to check for cancer spread, with medical affairs, promotional education and CME aimed at the nuclear medicine community.

The injection, green-lighted by FDA in March, is the first agent in 30 years to be approved for lymphatic mapping—basically analyzing lymph nodes for signs that a cancer has metastasized. It's sanctioned for use in breast cancer and melanoma. Sulfur Colloid, made by contract manufacturer Pharmalucence, is the only other radiopharmaceutical approved for lymph node localization in these cancers.

Lymphoseek will be sold and distributed in the US exclusively by Cardinal Health through its Nuclear Pharmacy Services. Navidea will deploy medical science liaisons (MSLs) to educate about lymphatic mapping and sentinel node biopsy to hospitals that practice nuclear medicine.

“We have aspirations to participate in the commercial side of the business, but only from a medical-education point of view,” said Thom Tulip, EVP, chief business officer for Navidea. Tulip said the MSL approach “lets us leverage what we learn in the clinic and pharmacy and apply it to not only educate customers to drive adoption [but] also to lift the overall top-line to make the market grow.”

He said Navidea's goal involves expanding Lymphoseek's market to other cancer types that lend themselves to lymphatic mapping. “The mechanism of action is not cancer-specific,” added Tulip, but may apply to “any solid tumor that drains into the lymphatics.”
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...